U.S. Markets closed

Is Neurocrine Biosciences (NBIX) a Great Growth Stock?

Zacks Equity Research

Growth stocks can be some of the most exciting picks in the market, as these high-flyers can captivate investors’ attention, and produce big gains as well. However, they can also lead on the downside when the growth story is over, so it is important to find companies which are still seeing strong growth prospects in their businesses.

One such company that might be well-positioned for future earnings growth is Neurocrine Biosciences, Inc. NBIX. This firm, which is in the Medical - Drugs industry, saw EPS growth of 113.5% last year, and is looking great for this year too.

In fact, the current growth estimate for this year calls for earnings-per-share growth of 263.6%. Furthermore, the long-term growth rate is currently an impressive 24%, suggesting pretty good prospects for the long haul.

Neurocrine Biosciences, Inc. Price and Consensus

Neurocrine Biosciences, Inc. Price and Consensus

Neurocrine Biosciences, Inc. price-consensus-chart | Neurocrine Biosciences, Inc. Quote

And if this wasn’t enough, the stock has actually seen estimates rise over the past month for the current fiscal year by about 364.2%. Thanks to this rise in earnings estimates, NBIX has a Zacks Rank #2 (Buy) which further underscores the potential for outperformance in this company. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

So if you are looking for a fast growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider NBIX. Not only does it have double-digit earnings growth prospects, but its impressive Zacks Rank suggests that analysts believe better days are ahead for NBIX as well.

Today's Best Stocks from Zacks

Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
 
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.

See their latest picks free >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Neurocrine Biosciences, Inc. (NBIX) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research